February 10, 2012International Journal of OncologyOpen Access

MEDI3617, a human anti-Angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models

View Full Paper

Ask AI

Bookmark

Why the study?

Does MEDI3617 inhibit angiogenesis and tumor growth in preclinical mouse models?

Population

Mouse models including FGF2-induced angiogenesis in a basement extract plug model, tumor and retinal…

Design

Preclinical

Authors

CLChing Ching LeowThe University of Texas MD Anderson Cancer Center

Discussion

Member takes

Implication

Preclinical activity of MEDI3617 does not alter cancer management; leaves open its clinical role pending human trials.

Structured PICO

Does MEDI3617 inhibit angiogenesis and tumor growth in preclinical mouse models?

Population

Mouse models including FGF2-induced angiogenesis in a basement extract plug model, tumor and retinal angiogenesis models, and mice bearing human tumor xenografts

Intervention

MEDI3617 (human anti-Angiopoietin 2 monoclonal antibody) as a single agent or in combination with chemotherapy or bevacizumab

Outcome

Inhibition of angiogenesis and tumor growthsurrogate

MEDI3617 demonstrates robust antiangiogenic and anti-tumor activity in preclinical models, supporting its clinical evaluation in cancer patients.

Cite This Study

Ching Ching Leow (2012) studied this question.

synapsesocial.com/papers/6a7ff20004731064ad46f266 https://doi.org/10.3892/ijo.2012.1366

View Full Paper

Ask AI

Bookmark

MEDI3617, a human anti-Angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models

Discussion

Member takes

Implication

Structured PICO

Cite This Study

MEDI3617, a human anti-Angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Also Consider